Further, CRC patients with increased expression of METTL3 (Fig. 8L), RRM2B (Fig. 8M), OPA1 (Fig. 8N) and IGF2BP2 (Fig. S8G) showed reduced overall survival (OS). This evidence concerns the gene IGF2BP2 and colorectal carcinoma.